One study reported that Factor V Leiden and prothrombin G20210A appear to contribute differently to the development CTEPH compared to PE alone and suggested that younger patients with PE who carry the Factor V Leiden mutation may be at a reduced risk of developing CTEPH [45]. This evidence concerns the gene F5 and chronic thromboembolic pulmonary hypertension.